|
|
Streptococcus gordonii vaccine vector |
|
Vaxvec ID |
26 |
|
Vaccine Vector Name |
Streptococcus gordonii vaccine vector |
|
Vector VO ID |
VO_0001036
|
|
Function |
The M6 protein from Streptococcus pyogenes is surface-localized with specific antigens on the surface of S. gordonii, which then expresses the antigen (Wang et al., 2013). |
|
Advantage |
As a regular resident of the oral cavity, a live,attenuated. gordonii strain is a good candidate for oral vaccine administration (Wang et al., 2013). Also, S. gordonii has been shown to activate antigen-presenting cells and induce their maturation (Mayer et al., 2009). Compared to Lactococcus lactis, S. gordonii is a superior vaccine vector for intestinal immunization (Lee et al., 2009). |
|
Disadvantage |
In order to elicit a necessary amount of cytokines, cytokines must be delivered externally because S. gordonii has been shown to be unable to elicit cytokines needed to suppress mucosal tolerance (Mayer et al., 2009) |
|
Description |
The S. gordonii M6 protein can be used to localize antigens, such as Sj-F1 of Schistosoma japonicum, on the surface of the bacterium, which induces an immune response against that antigen in the host (Wang et al., 2013). |
| Related Vaccine(s) |
|
| References |
Lee et al., 2009: Lee P, Abdul-Wahid A, Faubert GM. Comparison of the local immune response against Giardia lamblia cyst wall protein 2 induced by recombinant Lactococcus lactis and Streptococcus gordonii. Microbes and infection / Institut Pasteur. 2009; 11(1); 20-28. [PubMed: 18992359].
Mayer et al., 2009: Mayer ML, Phillips CM, Townsend RA, Halperin SA, Lee SF. Differential activation of dendritic cells by Toll-like receptor agonists isolated from the Gram-positive vaccine vector Streptococcus gordonii. Scandinavian journal of immunology. 2009; 69(4); 351-356. [PubMed: 19284500].
Mayer et al., 2009: Mayer ML, Phillips CM, Stadnyk AW, Halperin SA, Lee SF. Synergistic BM-DC activation and immune induction by the oral vaccine vector Streptococcus gordonii and exogenous tumor necrosis factor. Molecular immunology. 2009; 46(8-9); 1883-1891. [PubMed: 19278729].
Medaglini et al., 2001: Medaglini D, Ciabattini A, Spinosa MR, Maggi T, Marcotte H, Oggioni MR, Pozzi G. Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice. Vaccine. 2001; 19(15-16); 1931-1939. [PubMed: 11228363].
Oggioni et al., 1999: Oggioni MR, Medaglini D, Romano L, Peruzzi F, Maggi T, Lozzi L, Bracci L, Zazzi M, Manca F, Valensin PE, Pozzi G. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. AIDS research and human retroviruses. 1999; 15(5); 451-459. [PubMed: 10195755].
Pozzi et al., 1994: Pozzi G, Oggioni MR, Manganelli R, Medaglini D, Fischetti VA, Fenoglio D, Valle MT, Kunkl A, Manca F. Human T-helper cell recognition of an immunodominant epitope of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. Vaccine. 1994; 12(12); 1071-1077. [PubMed: 7998415].
Wang et al., 2013: Wang L, Liu W, Yang M, Peng D, Chen L. Development of a Streptococcus gordonii vaccine strain expressing Schistosoma japonicum Sj-F1 and evaluation of using this strain for intranasal immunization in mice. Parasitology research. 2013; 112(4); 1701-1708. [PubMed: 23403993].
|
|
